This manufacturing and collaboration agreement covers the clinical grade production of ExCellThera’s lead cell therapy product, ECT-001.
Zika virus remains a threat to public health due to its close association with microcephaly and other severe birth defects.
MERS-CoV, a newly emerging, highly pathogenic infectious virus, continues to threat public health worldwide with high mortality rate (about 35%).
We offer a comprehensive menu of services and products to support and manage the full spectrum of transfusion medicine, regenerative medicine and cellular-therapy related research projects, from basic science to full scale clinical trials.
New York Blood Center (NYBC) is one of the largest independent, community-based, nonprofit blood centers in the United States.